RUNX1 and neoplasm: RUNX1 has been implicated as a tumor suppressor in solid tumors, including breast cancer, esophageal adenocarcinoma, colon cancer, and possibly, prostate cancer and as an oncogene in skin cancer, endometrial cancer, and epithelial cancer (12).